ASX ANNOUNCEMENT

Monday, September 5th, 2005

GTG achieves NASDAQ National Market listing

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is very pleased to announce the listing of its Level II American Depositary Receipts (ADRs) on the National Association of Securities Dealers Automated Quotation (NASDAQ) stock market in the USA.

The Company's final Form 20-F Registration Statement was declared "effective" for the purposes of Securities and Exchange Commission compliance on Thursday, September 1st, 2005. The final listing on the NASDAQ National Market, under the ticker symbol GENE, occurred on Friday, September 2nd, 2005 (New York time) and the first sale of the Level II ADRs occurred at US$11.00. As advised previously, each ADR comprises 30 fully paid ordinary shares in the Company.

This listing now concludes what has been a lengthy and complex process. The successful completion of this long-awaited program provides GTG with invaluable exposure to a wide range of US and European investors and also access to the vast North American capital markets.

FOR FURTHER INFORMATION PLEASE CONTACT

Dr. Mervyn Jacobson, Executive Chairman, or
Mr. Tom Howitt, Company Secretary

Genetic Technologies Limited
Phone: +61 3 9415 1135